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Nanoparticles have attracted increasing attention for local drug delivery to the inner ear recently. Bovine serum
albumin (BSA) nanoparticles were prepared by desolvation method followed by glutaraldehyde fixation or heat
denaturation. The nanoparticles were spherical in shape with an average diameter of 492 nm. The heat-denatured
nanoparticles had good cytocompatibility. The nanoparticles could adhere on and penetrate through the round
window membrane of guinea pigs. The nanoparticles were analyzed as drug carriers to investigate the loading
capacity and release behaviors. Rhodamine B was used as a model drug in this paper. Rhodamine B-loaded
nanoparticles showed a controlled release profile and could be deposited on the osseous spiral lamina. We
considered that the bovine serum albumin nanoparticles may have potential applications in the field of local drug
delivery in the treatment of inner ear disorders.
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Inner ear disorders, including sensorineural hearing loss
(SSHL), commonly occur in clinics. The traditional sys-
temic therapies are almost ineffective due to the blood-
labyrinth barrier, which prevents the transport of drugs
from the serum. Local drug delivery, especially intratym-
panic injection, has become popular for two decades be-
cause of its efficiency and safety. The round window
membrane (RWM) is a semipermeable membrane bet-
ween the middle and the inner ear, through which parti-
cles less than 3 μm in diameter could penetrate.
Local drug delivery to the inner ear by intratympanic
injection was first described by Schuknecht in 1956 in
the treatment of Ménière's disease [1]. In 2006, Kopke
et al. reported a significant hearing improvement of* Correspondence: yuzhandz@126.com; ym77@163.com
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in any medium, provided the original work is ppatients with sudden sensorineural hearing loss after
methylprednisolone administration locally [2].
Although intratympanic injection is easy to perform in
the clinic, the loss of drug through the Eustachian tube
becomes the obstacle to treat inner ear disorders effi-
ciently. Thus, hydrogel- and particle-based vehicles (or
carriers) have been investigated recently for sustained and
prolonged drug supply. In 1998, Balough et al. described
that the local injection of a fibrin-based sustained release
vehicle impregnated with gentamicin allowed for a pro-
longed effect without absorption in the untreated ear or
blood [3]. Horie et al. reported that drug-loaded poly-
lactic/glycolic acid (PLGA) microparticles were capable of
delivering lidocaine into the cochlea in a sustained man-
ner [4]. The PLGA nanoparticles were found to be distri-
buted throughout the inner ear after application on the
RWM of chinchilla [5]. Moreover, Tan et al. demonstrated
that brain-derived neurotrophic factor encapsulated in
nanoporous poly(L-glutamic acid) particles could be re-
leased in a sustained manner with maintained biological
activity and efficiently rescue primary auditory neurons in
the cochlea of guinea pigs with sensorineural hearing loss
[6]. Nowadays, nanoparticles have received much morepen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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drug loading and sustained release capacity.
Various methods such as desolvation, emulsion, template,
microfluidic, mechanical stretching, and self-assembly
have been reported to prepare protein-based particles or
capsules [7-11]. In this study, we demonstrated that bo-
vine serum albumin (BSA) can form nanospheres by de-
solvation method and can be used for local drug delivery.
BSA is a natural protein able to form complexes in va-
rious shapes. This protein is biocompatible, biodegradable,
nontoxic, and nonimmunogenic. Due to these features,
albumin particles are a good system for drug and antigen
delivery [11-14]. To the best of our knowledge, there have
been no reports of local delivery of drug-loaded albumin
particles into the inner ear. Here, we illustrate a method
for creating sphere-shaped BSA nanoparticles (BSA-NPs)
with biocompatibility in high yield. A model drug, rho-
damine B (RhB), was loaded onto the BSA-NPs for drug
loading capacity, release, and in vivo studies. In vivo bio-
distribution suggested that the RhB released as well as the
RhB-loaded BSA-NPs (RhB-BSA-NPs) tended to accu-
mulate and penetrate through the RWM of guinea pigs.
Therefore, the BSA-NPs would be prospectively consi-
dered as controlled release carriers for local drug delivery
in the treatment of inner ear disorders.
Methods
Materials, mice, and cell culture
BSA and RhB were purchased from Sigma-Aldrich
(St. Louis, MO, USA). Cell counting kit-8 (CCK-8)
was purchased from Dojindo Molecular Technology Inc.
(Shanghai, People's Republic of China). Ultrapure water
used in all experiments was produced by Milli-Q synthesis
system (Millipore Corp., Billerica, MA, USA). L929 mouse
fibroblast cells (obtained from the Cancer Institute of the
Chinese Academy of Medical Sciences, People's Republic
of China) were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) (HyClone, Thermo Scientific Inc.,
Waltham, MA, USA) containing 10% fetal bovine serum
(FBS) at 37°C with 5% CO2. Guinea pigs weighing
250 ~ 300 g were purchased from the Tianjin Experimen-
tal Animal Center, People's Republic of China, and had
free access to food and water. Animal study protocols
were approved and performed in accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals.
Preparation of BSA-NPs and RhB-BSA-NPs
BSA-NPs were prepared by the desolvation method.
Briefly described, 100 mg of BSA was dissolved in 1 ml
of sodium chloride solution (10 mM). Then, 8.0 ml of
ethanol was added dropwise into the BSA solution under
magnetic stirring (400 rpm) at room temperature. Subse-
quently, the as-prepared BSA-NPs were cross-linkedwith 0.2% glutaraldehyde (GA) for 24 h or denatured at
70°C for 30 min. BSA-NPs (50 mg) were incubated with
certain amounts (5, 10, 15, 17.5, and 20 mg) of RhB for
2 h in the preparation of RhB-BSA-NPs. The particles
were centrifuged and washed with ultrapure water.
Characterization of the BSA-NPs
The morphological characteristics were determined by
transmission electron microscopy (TEM, JEOL, JEM-
100CXII, Akishima-shi, Japan), scanning electron micros-
copy (SEM, ZEISS SUPRA 55VP, Oberkochen, Germany),
and confocal laser scanning microscopy (CLSM, FV-1000,
Olympus Corporation, Shinjuku-ku, Japan). For TEM, a
drop of diluted suspension of BSA-NPs was placed on the
copper grid and the air-dried specimen was observed. For
SEM, a drop of diluted suspension was deposited on a sili-
con wafer. The air-dried sample was coated with gold and
observed. RhB-BSA-NPs were observed by CLSM at an
excitation wavelength of 555 nm and an emission wave-
length of 580 nm.
The BSA-NPs were dispersed in ultrapure water at a
concentration of 0.1 mg/ml. The particle size and zeta po-
tential determinations were performed by using a Malvern
particle size analyzer (Zetasizer Nano-ZS, Malvern, UK).
Drug loading capacity and encapsulation efficiency
BSA-NPs (50 mg) were incubated with RhB (5 ~ 20 mg)
for 2 h. After washing with ultrapure water, the superna-
tants were collected and analyzed for residual drug con-
centration by UV-vis analysis.
The drug loading capacity and encapsulation efficiency
were calculated as follows:
Drug loading w=w%ð Þ ¼ Amount of RhB in BSA‐NPs
=Amount of BSA‐NPs 100
Encapsulation efficiency (w / w%) = amount of RhB in
BSA-NPs/RhB initially added × 100
In vitro drug release behavior
The assay was evaluated in a standard static diffusion cell
at a speed of 100 rpm in a shaker at 37°C. The amount of
RhB was evaluated using UV-vis spectrometer (560 nm).
The amount of RhB released was evaluated at a series of
time points, and the release curve was made accordingly.
Cell biocompatibility assay
Cells were seeded in 96-well plates at a density of 1,000
cells/well. BSA-NPs with GA fixation (NP-GA) or heat
denaturation (NP-H) were added to each well for a 24-h
incubation. Cell viability was determined by CCK-8 assay.
Untreated cells served as the control. The morphology of
L929 cells in each group was also observed by using a
phase contrast microscope.
Figure 1 Morphology of BSA-NPs with heat denaturation and GA fixation. SEM/TEM images of BSA-NPs with heat denaturation (a) and GA
fixation (c) are shown. The size distribution of NP-H evaluated by DLS is shown in (b). The difference between the two kinds of NPs is shown in (d).
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Guinea pigs were killed to sample the acoustic bullae
(including the RWM). The acoustic bullae were placed
in the solution of BSA-NPs and shaking for 30 min at
37°C. The air-dried specimens were observed by SEM.Figure 2 Characteristics of RhB-loaded BSA-NPs. SEM (a), TEM (inset of
are demonstrated. The drug loading capacity, encapsulation efficiency (c),The penetration of RhB released from the RhB-BSA-
NPs was evaluated by live images and microscopes.
Guinea pigs were anaesthetized and the RWMs were
exposed. The heat-denatured RhB-BSA-NPs and RhB
dispersed in PBS were injected slowly into the bullae of(a)), and CLSM (b) images of RhB-loaded BSA-NPs denatured by heat
and controlled release profile (d) are shown respectively.
Figure 3 Cytotoxity evaluation of BSA-NPs fixed by GA or
denatured by heat against L929 cells. Each value represents
mean ± SD (n = 3) (**P < 0.01).
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with RhB solution was the control. In vivo imaging system
(Caliper IVIS imaging system, PerkinElmer, Waltham,
MA, USA) was used to trace the particles at time points
of 0 and 72 h. The RWM was then imaged by fluorescence
microscopy and SEM to observe the distribution of RhB
and BSA-NPs.
Statistical analysis
The statistical data was presented as the mean value and
standard deviation. The analysis of t test was used in SPSS
12.0 to determine significant differences between groups,Figure 4 Morphology of L929 cells cultured with different conditions.
CCK-8 assay (b), with the addition of NP-GA (c) and NP-H (d), are demonstratand P values less than 0.05 were considered statistically
significant.Results and discussion
Morphology of BSA-NPs
BSA-NPs were prepared by the desolvation method in
high yield (about 95%). Figure 1a and its inset display that
BSA-NPs with heat denaturation occur as solid spheres
with smooth surface. The size of these spheres determined
by dynamic light scattering (DLS) varied from 255 to
825 nm (Figure 1b). The mean value was 492 nm and was
larger than the size of 238 nm measured by SEM (ana-
lyzed by ImageJ 1.44 software) due to the shrinkage of the
particles during dehydration. The difference between SEM
and DLS is consistent with the previous literatures [8,15].
As shown in Figure 1c, BSA-NPs with GA fixation were
also sphere-shaped with a mean diameter of 320 nm.
Therefore, we can conclude that the morphology of BSA-
NPs shows no obvious difference in shape even if treated
by either heat or GA. However, there was little difference
between the particles viewed by the naked eye - the colors
of precipitates were yellow (Figure 1d, left) and milk white
(Figure 1d, right), respectively.Drug loading and release study
Rhodamine B was used as a model drug for observation
and evaluation of drug loading capacity. The morphology
and structure of RhB-loaded NP-H (Figure 2a) did not
change in comparison with those of BSA-NPs (Figure 1a).
The mean diameter of RhB-loaded NP-H was 636 nm, lar-
ger than that of BSA-NPs.L929 cells cultured in DMEM-10% FBS as the control (a), after performing
ed respectively. All images have an original magnification of × 200.
Figure 5 Live images revealed the distribution of RhB-BSA-NPs. RhB-BSA-NPs with heat denaturation were injected into the right ear, and
the images were taken immediately (a) and 72 h later (b). RhB solution injected into the left ear was the control.
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values of −15.4 and +4.98 mV, respectively. The poten-
tial difference demonstrated that the positively charged
RhB had an interaction with the negatively charged BSA
[8], which also promoted the attachment of RhB to
the BSA. The fluorescent image of the RhB-BSA-NPs
(Figure 2b) further confirmed that RhB had attached to
the BSA-NPs. Thus, the model drug and small molecules
could affect certain parameters including size and charge
of polymers, which was in agreement with the previous
reports [16-19].
The drug loading capacity and encapsulation efficiency
of BSA-NPs were also evaluated. The drug loading cap-
acity of BSA was 15.4% for RhB (Figure 2c). The ma-
ximum encapsulation efficiency was 40.9% (Figure 2c). It
was likely attributed to the electrostatic interaction and
hydrophobic interactions between RhB and BSA followed
by diffusion of the model drug into the BSA matrix [8,16].
Nevertheless, the drug cannot diffuse into the matrix
more after achieving the kinetic equilibrium state. The
results in this report were consistent with the report de-
scribed by Shi and Goh [8].
The in vitro drug release profile of RhB from BSA-NPs
is shown in Figure 2d. A good sustained release profile is
achieved. The cumulative release of RhB over a period of
150 hours was 429.14 μg, indicating a good affinityFigure 6 Images of RhB-BSA-NPs adhering on the RWM and osseous
the RWM was taken immediately after the surgery. The SEM image of RhB-
later. The aggregated BSA-NPs are shown in the inset (inset of (b)).between the BSA and RhB. This was governed by Fickian
diffusion due to the electrostatic interaction, which re-
stricted the release of positively charged RhB from nega-
tively charged BSA in vitro.
In vitro cytocompatibility study
In vitro experiment of BSA-NPs cross-linked with GA or
denatured by heat against L929 cell lines were performed
by CCK-8 to evaluate the cytocompatibility. As shown in
Figure 3, cell viability of NP-GA was significantly lower
(P = 0.001) than that of the control possibly because the
water wash in this study was only once. These results indi-
cated that the NP-H had a better cytocompatibility than
the NP-GA. The slight cytotoxicity of NP-GA was in
agreement with that reported by Speer [20]. There was no
statistical difference between the NP-H (P = 0.114) and
the control.
The shape of L929 cells incubated with NP-H main-
tained high viability after the assay (Figure 4d) while
round-shaped cells could be observed in the control and
NP-GA groups (Figure 4b,c). This indicated that the
addition of nontoxic NP-H might provide nutrition and
promote cell proliferation due to the hydrophobic do-
main of such natural protein, just as the silk fibroin par-
ticles did [8]. But the nutrition property of BSA on cell
proliferation cannot compensate the side effect of GA inspiral lamina. The fluorescent image of RhB-BSA-NPs (a) adhering on
BSA-NPs (b) deposited on the osseous spiral lamina was taken 3 days
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with the addition of NP-GA (Figure 4c). The above fin-
dings disclosed that BSA was not only a soft material
with good biocompatibility but also a nutrition provider.
Further studies will focus on the assessment of BSA-NP
drug delivery in the treatment of inner ear disorders.
In vivo distribution and drug delivery of BSA-NPs
As for the good cytocompatibility, BSA-NPs with heat
denaturation were loaded with RhB and used to evaluate
the local drug delivery. Acoustic bullae of guinea pigs
with entire RWM were isolated and injected with RhB-
BSA-NP (right ear) and RhB solution (left ear). The live
images were taken immediately (Figure 5a). Three days
later, there was still obvious fluorescent signals with a
larger area in the right ear (Figure 5b), which indicated
that RhB-BSA-NPs was retained nearby the RWM and
RhB possibly diffused into the Eustachian tube and the
inner ear. We assumed that the BSA-NPs maybe useful
for local drug delivery and controlled release. In the left
ear, there were only minimal fluorescent signals of RhB
(Figure 5b) because the RhB could penetrate through
the RWM by simple diffusion along its concentration
gradient.
The guinea pigs were then killed and the temporal
bones and RWMs were separated. The nanoparticles still
attached on the RWM (Figure 6a). The SEM image re-
vealed that particles aggregated on the osseous spiral
lamina and some particles even had penetrated into the
cochlea through the RWM (Figure 6b). As previously de-
scribed that PLGA nanoparticles or lipid core nanocap-
sules could pass through the RWM and be deposited in
various sites of the cochlea [5,21-23], we assumed that
the tiny BSA-NPs loaded with RhB could successfully
reach the inner ear through the RWM.
Conclusions
In summary, BSA-NPs were fabricated via a desolvation
method. The heat-denatured BSA-NPs had a great po-
tential application for local drug delivery into the coch-
lea to treat inner ear diseases due to the tiny size, good
biocompatibility, drug loading capacity, and controlled
release profile. Further studies will focus on the eva-
luation of drug-loaded BSA-NPs, including prednisolone.
We will evaluate their pharmacokinetics, pharmaco-
dynamics, and delivery mechanism in animal model.
The BSA-NPs also shed light in the treatment of human
inner ear diseases.
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